Measles-Rubella Vaccine Of Hyderabad Pharmacy Gets DCGI Nod

Measles-Rubella Vaccine Of Hyderabad Pharmacy Gets DCGI Nod,Measles-Rubella Vaccine Gets DCGI Nod,Hyderabad Pharmacy Gets DCGI Nod,Measles-Rubella Vaccine,Mango News,Indian Immunologicals gets DCGI nod,Hyderabad based Indian Immunologicals get Approval,IIL gets DCGI nod for Measles-Rubella vaccine,Indian Immunologicals wins DCGI okay,Latest DCGI News,Latest DCGI Information & Updates,Measles-Rubella Vaccine Latest News,Measles-Rubella Vaccine Latest Updates

The vaccine makers based in Hyderabad, Indian Immunologicals Limited (IIL), have received approval from the Drugs Controller General of India (DGCI) and Telangana State Drug Control Administration (TSDCA) for manufacturing its Measles-Rubella (MR) Vaccine.

As an outcome of the Indo-Vietnam partnership, the product has been in the works for more than six years and for which IIL is collaborating with Vietnam’s Center for Research and Production of Vaccines and Biologicals, also known as Polyvac.

Vietnam under Polyvac will supply the Measles vaccine to Indian Immunologicals while the Rubella vaccine will be produced by IIL to manufacture a combined MR vaccine.

The live attenuated MR vaccine is an addition to the list of several other vaccines that IIL supplies to the Universal Immunization Programme (UIP) of India.

“The MR vaccine of IIL has been proven through extensive human clinical trials to be immunogenic and safe for people of 9 months to 49 years,” stated a press release.

Managing director of IIL, Dr K Anand Kumar, while speaking on the occasion said, “We started with humble beginnings with Polyvac in 2016 and worked tirelessly throughout including the tough Covid-19 period.”

Stay tuned for further updates.

Mango News Link


Google Play Store:

Apple / iOS Store:


Please enter your comment!
Please enter your name here